最近の造血薬理学について ―EPO, G-CSF, TPOの開発および作用メカニズム―

鳥居 義史

doi:10.7130/hokkaidoshakai.26.3_85

[title in Japanese]

[in Japanese]

Author information

Keywords: G-CSF

JOURNAL FREE ACCESS

1999 Volume 26 Issue 3 Pages 85-92

DOI https://doi.org/10.7130/hokkaidoshakai.26.3_85

Details

Published: August 25, 1999 Received: - Available on J-STAGE: June 28, 2010 Accepted: - Advance online publication: - Revised: -
Correction information
Date of correction: June 28, 2010 Reason for correction: - Correction: KEYWORD Details: Right : G-CSF

Date of correction: June 28, 2010 Reason for correction: - Correction: CITATION Details: Wrong : E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E

Right : 1)Miyake T, Kung CKH, Goldwasser E: Purification human erythropoietin. J Biol Chem, 252; 5558-5564, 1977.
3)D'Andrea AD, Lodish HF, Wong GG, et al.: Expression cloning of the murine erythropoietin receptor. Cell, 57; 277-285, 1989.
4)Wrighton NC, Farrell FX, Chang R, et al.: Small Peptides as potent mimetics of the protein hormone erythropoietin. Science 273; 458-463, 1996.
5)Syed RS, Reid SW, Li C, et al.: Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature, 395; 511-516, 1998.
6)Ye X, Rivera VM, Zoltick P, et al.: Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science, 283; 88-91, 1999.
7)Rendahl KG; Leff SE; Otten GR, et al.: Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol, 16; 757-761, 1998.
9)Welte K, Patzer E, Lu L, et al.: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Nat Acad Sci, 82; 1526-1530, 1985.
10)Souza LM, Boone TC, Gabrilove J, et al.: Recombinant human granulocyte colony-stimulat-ing factor: Effects on normal and leukemic myeloid cells. Science, 232; 61-65, 1986.
11)Watanabe M, Uzumaki K, Fukamachi H, et al.: Effects of sugar chains on biological activities of human granulocyte colony-stimulating factor(GCSF). Int J Hematol, 54; 217, 1991.
12)Lieschke GJ, Grail D, Hodgson G, et al.: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood, 84; 1737-1746, 1994.
14)Fukunaga R, Ishizak-Ikeda E, Seto Y, et al.: Expression cloning of a receptor for murine granulocyte colony-stimulating factor. Cell, 61; 341-350, 1990.
15)Demetri GD, Griffin JD: Granulocyte colony stimulating factor and its receptor. Blood, 78; 2791-2808, 1991.
16)Miyajima A, Ito Y, Kinoshita T: Cytokine signaling for proliferation, survival, and death in hematopoietic cells. Int J Hematol, 69, 137-146, 1999.
17)Kato T, Ogami K, Shimada Y, et al.: Purification and characterization of thrombopoietin. J Biochem, 118; 229-236, 1995.
18)Sohma Y, Akahori H, Seki N, et al.: Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS lett, 353; 57-61, 1994.
19)Kabaya K, Akahori H, Shibuya K, et al.: In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells, 14; 651-660, 1996.
20)Akahori H, Shibuya K, Ozai M, et al.: Effects of pegylated recombinant human megakaryocyte growth and development factor on throm-bocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells, 14; 678-689, 1996.
21)Kabaya K, Shibuya K, Torii Y, et al.: Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice. Bone Marrow Transplant, 18; 1035-1041, 1996.
22)Shibuya K, Akahori H, Takahashi K, et al.: Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood, 91; 37-45, 1998.
23)Akahori H, Ozai M, Ida M, et al.: Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on throm-bocytopenia in myelosuppressed mice. Ther Apher, 2; 58-64, 1998.
24)Kobayashi M, Laver JH, Kato T, et al.: Throm-bopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin 3. Blood, 88; 429-436, 1996.
25)Kobayashi M, Laver JH, Kato T, et al.: Recombinant human thrombopoietin(Mplligand)enhances proliferation of erythroid progenitors.Blood, 86; 2494-2499, 1995.
26)Torii Y, Nitta Y, Akahori H, et al.: Mobilization of primitive haematopoietic progenitor cells and stem cells with long-term repopulating ability into peripheral blood in mice by pegylated recombinant human megakaryocyte growth and development factor. Br J Haematol, 103; 1172-1180, 1998.
27)Basser RL, Rasko JEJ, Clarke K, et al.: Throm-bopoietic effects of pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF)in patients with advanced cancer. Lancet, 348; 1279-1281, 1996.
28)O'Malley CJ, Rasko JEJ, Basser RL, et al.: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the produnction of functional platelets that no evidence of in vivo action. Blood, 88; 3288-3298, 1996.
29)Basser RL, Clarke K, Rasko JEJ, et al.: Randomized, blinded placebo-controlled phase 1 trial of pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF)with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood89; 3118-3128. 1997.

Corresponding author

Correction information

Register with J-STAGE for free!